VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of the expression of BH3-only protein genes in mice and rats

Journal of Clinical Investigation

Volumn 118, Issue 3, 2008, Pages 913-923

  Li, Yang ^a   Zhang, Fan ^a   Nagai, Nobuo ^b   Tang, Zhongshu ^a   Zhang, Shuihua ^a   Scotney, Pierre ^c   Lennartsson, Johan ^d   Zhu, Chaoyong ^a   Qu, Yi ^a   Fang, Changge ^a   Hua, Jianyuan ^a   Matsuo, Osamu ^b   Fong, Guo Hua ^e   Ding, Hao ^f   Cao, Yihai ^g   Becker, Kevin G ^h   Nash, Andrew ^c   Heldin, Carl Henrik ^d   Li, Xuri ^a  

^a NATIONAL EYE INSTITUTE   (United States)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c CSL LIMITED   (Australia)

^d UPPSALA UNIVERSITY   (Sweden)

^e UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^f UNIVERSITY OF MANITOBA   (Canada)

^g KAROLINSKA INSTITUTE   (Sweden)

^h NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BH3 PROTEIN; CASPASE; PROTEIN P53; VASCULOTROPIN B; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG INHIBITION; EYE DISEASE; FEMALE; GENE EXPRESSION; MOUSE; NERVE DEGENERATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; RAT; REAL TIME POLYMERASE CHAIN REACTION; RETINA DEGENERATION; RETINA NEOVASCULARIZATION; SINGLE DRUG DOSE; SMOOTH MUSCLE FIBER; STROKE;

ANIMALS; APOPTOSIS; CELLS, CULTURED; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; OXIDATIVE STRESS; RATS; RETINA; VASCULAR ENDOTHELIAL GROWTH FACTOR B; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 40549090548     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI33673     Document Type: Article

References (53)

1. Folkman, J. 2007. Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Discov. 6:273-286.
2. Ferrara, N., and Kerbel, R.S. 2005. Angiogenesis as a therapeutic target. Nature. 438:967-974.
3. Carmeliet, P., and Jain, R.K. 2000. Angiogenesis in cancer and other diseases. Nature. 407:249-257.
4. Luttun, A., et al. 2002. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat. Med. 8:831-840.
5. Alitalo, K., Tammela, T., and Petrova, T.V. 2005. Lymphangiogenesis in development and human disease. Nature. 438:946-953.
6. Carmeliet, P., and Tessier-Lavigne, M. 2005. Common mechanisms of nerve and blood vessel wiring. Nature. 436:193-200.
7. Greenberg, D.A., and Jin, K. 2005. From angiogenesis to neuropathology. Nature. 438:954-959.
8. Li, X., and Eriksson, U. 2001. Novel VEGF family members: VEGF-B, VEGF-C and VEGF-D. Int. J. Biochem. Cell Biol. 33:421-426.
9. Nash, A.D., Baca, M., Wright, C., and Scotney, P.D. 2006. The biology of vascular endothelial growth factor-B (VEGF-B). Pulm. Pharmacol. Ther. 19:61-69.
10. Olofsson, B., et al. 1996. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 93:2576-2581.
11. Olofsson, B., et al. 1998. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 95:11709-11714.
12. Li, X., Aase, K., Li, H., von Euler, G., and Eriksson, U. 2001. Isoform-specific expression of VEGF-B in normal tissues and tumors. Growth Factors. 19:49-59.
13. Aase, K., et al. 1999. Localization of VEGF-B in the mouse embryo suggests a paracrine role of the growth factor in the developing vasculature. Dev. Dyn. 215:12-25.
14. Ferrara, N., et al. 1996. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 380:439-442.
15. Carmeliet, P., et al. 1996. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 380:435-439.
16. Aase, K., et al. 2001. Vascular endothelial growth factor-B-deficient mice display an atrial conduction defect. Circulation. 104:358-364.
17. Bellomo, D., et al. 2000. Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. Circ. Res. 86:E29-E35.
18. Reichelt, M., et al. 2003. Vascular endothelial growth factor-B and retinal vascular development in the mouse. Clin. Experiment. Ophthalmol. 31:61-65.
19. Louzier, V., et al. 2003. Role of VEGF-B in the lung during development of chronic hypoxic pulmonary hypertension. Am. J. Physiol. Lung Cell Mol. Physiol. 284:L926-L937.
20. Rissanen, T.T., et al. 2003. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ. Res. 92:1098-1106.
21. Bhardwaj, S., et al. 2003. Angiogenic responses of vascular endothelial growth factors in periadventitial tissue. Hum. Gene Ther. 14:1451-1462.
22. Brkovic, A., and Sirois, M.G. 2007. Vascular permeability induced by VEGF family members in vivo: Role of endogenous PAF and NO synthesis. J. Cell. Biochem. 100:727-737.
23. Abraham, D., et al. 2002. VEGF-A and -C but not -B mediate increased vascular permeability in preserved lung grafts. Transplantation. 73:1703-1706.
24. Mould, A.W., et al. 2005. Transgenic overexpression of vascular endothelial growth factor-B isoforms by endothelial cells potentiates postnatal vessel growth in vivo and in vitro. Circ. Res. 97:e60-e70.
25. Silvestre, J.S., et al. 2003. Vascular endothelial growth factor-B promotes in vivo angiogenesis. Circ. Res. 93:114-123.
26. Wright, C.E. 2002. Effects of vascular endothelial growth factor (VEGF)A and VEGFB gene transfer on vascular reserve in a conscious rabbit hindlimb ischaemia model. Clin. Exp. Pharmacol. Physiol. 29:1035-1039.
27. Tammela, T., Enholm, B., Alitalo, K., and Paavonen, K. 2005. The biology of vascular endothelial growth factors. Cardiovasc. Res. 65:550-563.
28. Wanstall, J.C., et al. 2002. Vascular endothelial growth factor-B-deficient mice show impaired development of hypoxic pulmonary hypertension. Cardiovasc. Res. 55:361-368.
29. Puthalakath, H., et al. 2001. Bmf: a proapoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis. Science. 293:1829-1832.
30. Okamura, S., et al. 2001. p53DINP1, a p53-inducible gene, regulates p53-dependent apoptosis. Mol. Cell. 8:85-94.
31. Seidler, D.G., et al. 2006. Decorin protein core inhibits in vivo cancer growth and metabolism by hindering epidermal growth factor receptor function and triggering apoptosis via caspase-3 activation. J. Biol. Chem. 281:26408-26418.
32. Scotney, P.D., et al. 2002. Human vascular endothelial growth factor B: characterization of recombinant isoforms and generation of neutralizing monoclonal antibodies. Clin. Exp. Pharmacol. Physiol. 29:1024-1029.
33. Sun, Y., et al. 2004. Increased severity of cerebral ischemic injury in vascular endothelial growth factor-B-deficient mice. J. Cereb. Blood Flow Metab. 24:1146-1152.
34. Nishijima, K., et al. 2007. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am. J. Pathol. 171:53-67.
35. Ferrara, N., et al. 1996. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 380:439-442.
36. Karkkainen, M.J., et al. 2004. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat. Immunol. 5:74-80.
37. Dvorak, H.F., Brown, L.F., Detmar, M., and Dvorak, A.M. 1995. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146:1029-1039.
38. Carmeliet, P., et al. 2001. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 7:575-583.
39. Joukov, V., et al. 1997. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J. 16:3898-3911.
40. Rosenfeld, P.J., Rich, R.M., and Lalwani, G.A. 2006. Ranibizumab: Phase III clinical trial results. Ophthalmol. Clin. North Am. 19:361-372.
41. Vredenburgh, J.J., et al. 2007. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin. Cancer Res. 13:1253-1259.
42. Shih, S.C., Ju, M., Liu, N., and Smith, L.E. 2003. Selective stimulation of VEGFR-1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurity. J. Clin. Invest. 112:50-57.
43. Plate, K.H., Beck, H., Danner, S., Allegrini, P.R., and Wiessner, C. 1999. Cell type specific upregulation of vascular endothelial growth factor in an MCA-occlusion model of cerebral infarct. J. Neuropathol. Exp. Neurol. 58:654-666.
44. Gerber, H.P., et al. 2002. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature. 417:954-958.
45. Shih, S.C., et al. 2003. Transforming growth factor beta1 induction of vascular endothelial growth factor receptor 1: mechanism of pericyte-induced vascular survival in vivo. Proc. Natl. Acad. Sci. U. S. A. 100:15859-15864.
46. Bates, R.C., et al. 2003. Flt-1-dependent survival characterizes the epithelial-mesenchymal transition of colonic organoids. Curr. Biol. 13:1721-1727.
47. Gariano, R.F., Hu, D., and Helms, J. 2006. Expression of angiogenesis-related genes during retinal development. Gene Expr. Patterns. 6:187-192.
48. Beck, H., et al. 2002. Cell type-specific expression of neuropilins in an MCA-occlusion model in mice suggests a potential role in post-ischemic brain remodeling. J. Neuropathol. Exp. Neurol. 61:339-350.
49. Moreno-Flores, M.T., et al. 2003. Semaphorin 3C preserves survival and induces neuritogenesis of cerebellar granule neurons in culture. J. Neurochem. 87:879-890.
50. Seidel, M.F., Simard, J.M., Hunter, S.F., and Campbell, G.A. 1991. Isolation of arteriolar microvessels and culture of smooth muscle cells from cerebral cortex of guinea pig. Cell Tissue Res. 265:579-587.
51. Nagai, N., Vanlinthout, I., and Collen, D. 1999. Comparative effects of tissue plasminogen activator, streptokinase, and staphylokinase on cerebral ischemic infarction and pulmonary clot lysis in hamster models. Circulation. 100:2541-2546.
52. Darby, I.A., Bisucci, T., Desmouliere, A., and Hewitson, T.D. 2006. In situ hybridization using cRNA probes: isotopic and nonisotopic detection methods. Methods Mol. Biol. 326:17-31.
53. Li, X., et al. 2000. PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. Nat. Cell Biol. 2:302-309.